Pfizer gets FDA approval for rheumatoid arthritis treatment

Share this article:
Federal regulators approved Pfizer's new Xeljanz treatment for rheumatoid arthritis Tuesday. The potentially lucrative drug is now poised to enter a market that already features Humira, Abbott Laboratories' top-selling rheumatoid arthritis treatment.

The Food and Drug Administration approved Xeljanz for patients with moderate to severe rheumatoid arthritis who did not benefit from the oral treatment methotrexate. Xeljanz can be used with methotrexate and certain other treatments. Industry analysts have predicted the new drug, also known as tofacitinib, could grow to sales of $3 billion annually.

Xeljanz is taken in 5-milligram pills twice daily. Abbott's $8 billion-a-year Humira requires an injection every two weeks. The FDA said it requires more safety data on a 10-milligram, twice-daily dose of Xeljanz that  Pfizer also submitted.

About 1.3 million people in the United States suffer from rheumatoid arthritis, which can cause problems in wounds healing.

Share this article:

More in News

NY nursing home agrees to $2.2 million settlement in case of false documentation

NY nursing home agrees to $2.2 million settlement ...

Nursing home operator Ralex Services Inc. has agreed to a $2.2 million settlement in a whistleblower case involving forged documents at a facility in New Rochelle, New York.

Common soaps could endanger healthcare workers, study finds

Healthcare facilities should consider replacing antibacterial soaps containing the chemical triclosan, University of California-San Francisco researchers assert in a recent Journal of Occupational and Environmental Medicine article. The conclusion echoes recently updated hand hygiene guidelines.

Mandatory staff hours, better high-acuity care could improve quality of life in ...

A nursing home's staffing patterns and admissions trends are among the most important factors driving residents' quality of life over time, according to recently published research findings.